1. Shun Kaneko, Yasuhiro Asahina, Miyako Murakawa, Ryuichi Okamoto. Liver stiffness stratify the disease progression and hepatocellular carcinoma predictive risk score on chronic hepatitis B patients. JDDW2023 2023.11.03

  2. Mina Nakagawa, Miyako Murakawa, Masato Miyoshi, Shun Kaneko, Fukiko Kawai-Kitahata, Sayuri Nitta, Sei Kakinuma, Yasuhiro Asahina, Ryuichi Okamoto. Factors associated with HCC development and patients’ survival in patients with an SVR. The 3rd JSH International Liver Conference 2023.09.07

  1. Yasuhiro Asahina. HCC development and surveillance after SVR. JDDW 2022, JSH-AASLD joint symposium 2022.10.27

  1. Mina Nakagawa, Masato Miyoshi, Fukiko Kawai-Kitahata, Miyako Murakawa, Sayuri Nitta, Yasuhiro Itsui, Seishin Azuma, Sei Kakinuma, Yasuhiro Asahina. Factors associated with HCC development and patients’ survival in patients with an SVR. JSH International Liver Conference 2021 2021.10.03

  1. Fukiko Kawai-Kitahata, Yasuhiro Asahina , Sei Kakinuma, Miyako Murakawa, Sayuri Nitta, Masato Miyoshi, Ayako Sato, Jun Tsuchiya, Taro Shimizu, Eiko Takeichi, Mina Nakagawa, Yasuhiro Itsui, Seishin Azuma, Shinji Tanaka , Minoru Tanabe, Shinya Maekawa, Nobuyuki Enomoto and Mamoru Watanabe. Comprehensive analysis of cancer-related genes and AAV/Hepatitis B virus integration into genome on development of hepatocellular carcinoma in patients with prior Hepatitis B virus infection. EASL The Digital International Liver Congress 2020 2020.08.28 Online

  1. Yasuhiro Asahina. Do DAA therapy result in an increased risk of hepatocarcinogenesis?. Asian Pacific Digestive Week 2019 2019.12.13 Kolata（India）

  2. Yasuhiro Asahina, Fukiko Kawai-Kitahata, Miyako Murakawa, Sayuri Nitta, Yasuhiro Itsui, Mina Nakagawa, Seishin Azuma, Sei Kakinuma. Comprehensive analysis of cancer gene mutations and viral integration in hepatocellular carcinoma arising from non-fibrotic liver. AASLD The Liver Meeting 2019 2019.11.10 Boston（USA）

  3. Yasuhiro Asahina. Prevention and Risk for Liver Cancer after Anti-Viral Therapy in Patients with HBV/HCV. JSH International Liver Conference 2019.10.02 Osaka（Japan）

  4. Miyako Murakawa, Yasuhiro Asahina, Emi Inoue, Mina Nakagawa, Jun Tsuchiya, Ayako Sato, Masato Miyoshi, Tomoyuki Tsunoda, Fukiko Kawai-Kitahata, Sayuri Nitta, Yasuhiro Itsui, Seishin Azuma, Sei Kakinuma, Mamoru Watanabe. The association of serum IFN-lambda 3 levels with liver fibrosis and hepatocarcinogenesis in chronic hepatitis C patients treated with direct-acting antiviral agents. EASL, The International Liver Congress 2019 2019.04.13 Vienna （Austria）

  5. Mina Nakagawa, Yasuhiro Asahina, Jun Tsuchiya, Ayako Sato, Tomoyuki Tsunoda, Masato Miyoshi, Emi Inoue, Fukiko Kawai-Kitahata, Miyako Murakawa, Sayuri Nitta, Yasuhiro Itsui, Seishin Azuma, Sei Kakinuma, Makoto Tomita, Mamoru Watanabe. Impact of HCV clearance on HCC development and patient survival: Propensity score-matched analysis of an ongoing database of 2173 CHC patients. EASL, The International Liver Congress 2019 2019.04.13 Vienna（Austria）

  1. Asahina Y. Increased risk of HCC following DAA: fact or fiction? / Follow up strategy after SVR in chronic hepatitis C. Asian Pacific Digestive Week 2018 2018.11.16 Seoul（Korea）

  2. Nakagawa M, Asahina Y, Kawai-Kitahata F, Murakawa M, Nitta S, Itsui Y, Azuma S, Kakinuma S, Tomita M, Watanabe M. Post-Treatment M2BPGi Level Is Useful for Predicting HCC Occurrence and Recurrence after Viral Eradication in Chronic Hepatitis C Patients. AASLD, The Liver Meeting 2018 2018.11.10 San Francisco (USA）

  3. Nitta S, Kato T, Tuchiya J, Sato A, Tsunoda T, Miyoshi M, Inoue- Shinomiya E, Kawai-Kitahata F, Murakawa M, Itsui Y, Nakagawa M, Azuma S, Kakinuma S, Asahina Y. The Characteristic and the Anti-HCV Reagents Susceptibility Analysis of NS5A Resistance-Associated Substitutions (RAS) Detected after Daa Treatment Failure Patients. AASLD, The Liver Meeting 2018 2018.11.10 San Francisco (USA）

  4. Asahina Y, Kawai-Kitahata F, Murakawa M, Nitta S, Nakagawa M, Kakinuma S, Watanabe M. Gene Mutational Profile and Viral Integration in Hepatocellular Carcinoma with or without HBV/HCV Suppression. AASLD, The Liver Meeting 2018 2018.11.10 San Francisco（USA）

  5. Nitta S, Kato T, Tuchiya J, Shinomiya-Inoue E, Sato A, Tsunoda T, Miyoshi M, Kitahata-Kawai F, Murakawa M, Istui Y, Azuma S, Nakagawa M, Kakinuma S, Asahina Y. The in vitro analysis of NS5A resistance-associated substitutions (RAS) observed in DAA treatment failure patients. 25th International Symposium on Hepatitis C Virus and Related Viruses 2018.10.09 Dublin（Ireland）

  6. Kitahata-kawai F, Asahina Y, KakinumaS, Murakawa M, Nitta S, Nagata H, Kaneko S, Inoue E, Miyoshi M, Tsunoda T, Sato A, Nakagawa M, Itsui Y, Azuma S, Tanaka S, Tanabe M, Maekawa S, Enomoto N and Watanabe M. Difference of gene mutational profile among viral- and non-viral HCC with or without prior HBV infection: Results of comprehensive deep sequencing analyses of cancer genes and HBV/A AV integration. EASL, The International Liver Congress 2018 2018.04.14 Paris（France）

  7. Asahina Y, Kakinuma S . HBV reactivation and changes in interferon-stimulated gene expression during treatment of direct-acting antivirals for HCV: Analyses in a novel in vitro model for HBV-HCV coinfection using human induced pluripotent stem cell-derived hepatic cells . EASL, The International Liver Congress 2018 2018.04.14 Paris（France）

  8. Asahina Y, Liu CJ, Gane E, Itoh Y, Kawada N, Ueno Y, Wang CY, Llewellyn J, Osinusi A, Svarovskaia J, Mo H, Crans G, Chuang WL, Chen PJ, Enomoto N. Ledipasvir/Sofosbuvir All-oral Regimen for Patients with Chronic Hepatitis C Genotype 2 Infection: Integrated Analysis of Three Clinical Studies. 27th Annual Conference of the Asian Pacific Association for the Study of the Liver 2018.03.15 Dehli（India）

  9. Asahina Y. Host genome mutations and HBV integration in HCC patients with HBV infection. 36th US-Japan Hepatitis Panel Meeting 2018.01.10 Shenzhen（China）

  1. 朝比奈靖浩. Gap between real world data and the clinical trial with DAA for HCV. TASL2017 2017.12.10 台湾

  2. 朝比奈靖浩. Occurrence and recurrence of hepatocellular carcinoma (HCC) in HCV patients treated with direct acting antiviral agents.. KDDW2017 2017.11.23 Seoul (Korea)

  3. Kaneko S, Kakinuma S, Asahina Y, Kamiya A, Miyoshi M, Tsunoda T, Inoue-Shinomiya E, Nitta S, Sato A, Asano Y, Nagata H, Kawai-Kitahata F, Murakawa M, Itsui Y, Nakagawa M, Azuma S, Watanabe M. A novel culture model for coinfection of hepatitis B and hepatitis C viruses using human induced pluripotent stem cell–derived hepatic cells for analyses of changes in host-innate immune responses . AASLD The Liver Meeting 2017 2017.10.22 Washington DC

  4. Nakagawa M, Asahina Y, Nagata H, Kaneko S, Kawai-Kitahata F, Murakawa M, Nitta S, Itsui Y, Azuma S, Kakinuma S, Tanaka Y, Watanabe M. Evaluation of an early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C patients treated with All-Oral DAAs - propensity score-matched analysis of a prospective database -. AASLD, The Liver Meeting 2017 2017.10.22 Washington D.C (USA）

  5. Murakawa M, Asahina Y, Nakagawa M, Nitta S, Kawai-Kitahata F, Nagata H, Kaneko S, Asano Y, Miyoshi M, Tsunoda T, Inoue-Shinomiya E, Sato A, Itsui Y, Kakinuma S, Azuma S, Watanabe M. On-treatment higher levels of alpha-fetoprotein and M2BPGi are associated with development of hepatocellular carcinoma during nucleos(t)ide analog therapy in patients with HBV chronic infection. AASLD, The Liver Meeting 2017 2017.10.21 Washington DC (USA)

  6. Nitta S, Murakawa M, Kato T, Sato A, Tsunoda T, Miyoshi M, Asano Y, Kaneko S, Nagata H, Kawai-Kitahata F, Itsui Y, Nakagawa M, Azuma S, Kakinuma S, Asahina Y. The analysis of NS5A Resistance-Associated Substitutions (RAS): In vitro study of NS5A recombinant hepatitis C in infectious cell culture system for various RAS detected after treatment failure in chronic hepatitis C patients. AASLD The Liver Meeting 2017 2017.10.21 Washington D.C (USA）

  7. HCC with or without viral suppression and new predictive biomarkers.. Taiwan Digestive Diseases Week 2017 2017.10.01

  8. Azuma S, Asahina Y, Kakinuma S, Azuma K, Watanabe M.. Diabetic retinopathy as a risk factor associated with development of hepatocellular carcinoma in non-alcoholic fatty liver disease.. Asian Pacific Digestive Week 2017.10.01

  9. Seishin Azuma, Yasuhiro Asahina, Sei Kakinuma, Keiko Azuma, Mamoru Watanabe. Diabetic retinopathy as a risk factor associated with development of hepatocellular carcinoma in non-alcoholic fatty liver disease. Asian Pacific Digestive Week 2017 2017.09.25 香港

  10. Kawai-Kitahata F, Asahina Y, Kakinuma S, Murakawa M, Niita S, Nagata H, Kaneko S, Otani S, Miyoshi M, Tsunoda T, Sato A, Nakagawa M, Itsui Y, Azuma S, Tanaka S, Tanabe M, Maekawa S, Enomoto N, Watanabe M. Genetic differences in hepatocellular carcinoma among chronic persistent hepatitis B virus infection with or without viral suppression and prior hepatitis B virus infection. EASL The International Liver Congress 2017 2017.04.20 Amsterdam （Netherlands）

  1. Seto WK, Asahina Y, Peng CY, Stanciu C, Abdurakhmanov D, Flaherty JF, Kim K, Gaggar A, Subramanian M, Tabak F, Nguyen TT, Chan HLY.. Reduced Changes In Bone Mineral Density In CHB Patients Receiving Tenofovir Alfenamide (TAF) Compared With Tenofovir disoproxil fumarate.. 2016.11.11

  2. Shun Kaneko, Sei Kakinuma, Yasuhiro Asahina, Akihide Kamiya, Masato Miyoshi, Tomoyuki Tsunoda, Sayuri Nitta, Ayako Sato, Yu Asano, Hiroko Nagata, Satoshi Otani, Fukiko Kawai-Kitahata, Miyako Murakawa, Yasuhiro Itsui, Mina Nakagawa, Seishin Azuma, Mamoru Watanabe. Genetically modified human induced pluripotent stem cell-derived hepatic progenitor-like cell lines as a model for interaction between hepatitis B virus and host cells. AASLD The Liver meeting 2016 2016.11.11 Boston（USA）

  3. Wai-Kay Seto , Yasuhiro Asahina , Cheng-Yuan Peng , Carol Stanciu , Djamal Abdurakhmanov , John F. Flaherty , Kyungpil Kim , Anuj Gaggar , Mani Subramanian, Fehmi Tabak, Tuan T. Nguyen, Henry Lik-Yuen Chan. Reduced Changes In Bone Mineral Density In CHB Patients Receiving Tenofovir Alfenamide (TAF) Com-pared With Tenofovir disoproxil fumarate. AASLD The Liver meeting 2016 2016.11.11 Boston（USA）

  4. Asahina Y. 【International Session（Symposium）1】Genomics of hepatocellular carcinoma: Hepatitis virus infection and hepatocarcinogenesis. Chair . JDDW2016 2016.11.03 Kobe Cinvention Center（Kobe JAPAN）

  5. Asahina Y. Recent progress in anti-HCV therapy and challenges toward HCC eradication.. Academic Forum of Liver Disease in Northeast China and the Annual Convention for the Study of Liver Diseases in Jilin Province in 2016. 2016.10.29 Changchun（China）

  6. Asahina Y. Hepatocarcinogenesis after hepatitis C viral eradication.. The 10th APASL Single Topic Conference 2016.06.08 Kaoshiung（Taiwan）

  7. Kaneko S, Kakinuma S, Asahina Y, Kamiya A, Nitta S, Tsunoda T, Miyoshi M, Asano Y, Nagata H , Goto F, Otani S, Kitahata F, Murakawa M, Itsui Y, Nakagawa M, Azuma S, Watanabe M. A new model for studying interaction between hepatitis B virus and host cells derived from human induced pluripotent stem cells.. EASL The International Liver Congress 2016 2016.04.14 Barcelona（Spain）

  8. Kawai-Kitahata F, Asahina Y, Tanaka S, Kakinuma S, Murakawa M, Nitta S, Otani S, Goto F, Nagata H, Kaneko S, Asano Y, Miyoshi M, Tsunoda T, Azuma S, Itsui Y, Nakagawa M, Tanabe M, Maekawa S, Enomoto N, Watanabe M. Comprehensive analyses of mutations and hepatitis B virus integration in hepatocellular carcinoma. The 25th Asian Pacific Association for the Study of the Liver 2016.02.22 International Convention Center Pamir, Tokyo（JAPAN）

  9. Kaneko S, Kakinuma S, Asahina Y, Kamiya A, Nitta S, Tsunoda T, Miyoshi M, Asano Y, Nagata H , Goto F, Otani S, Kitahata F, Murakawa M, Itsui Y, Nakagawa M, Azuma S, Watanabe M. A Model for Interaction between HBV and Host Cells Derived from Human Induced Pluripotent Stem Cells.. The 25th Asian Pacific Association for the Study of the Liver 2016.02.22 International Convention Center Pamir, Tokyo（JAPAN）

  10. Nagata H, Sakurai Y, Nakagawa M, Kakinuma S, Azuma S, Murakawa M, Nitta S, Itsui Y, Asahina Y, Watanabe M. Serial changes in M2BPGi levels as predictors of fibrosis and HCC in chronic hepatitis C. The 25th Asian Pacific Association for the Study of the Liver 2016.02.22 International Convention Center Pamir, Tokyo（JAPAN）

  11. Asahina Y. 【HCV 5】Chair. The 25th Asian Pacific Association for the Study of the Liver 2016.02.22 International Convention Center Pamir, Tokyo（JAPAN）

  12. Asahina Y. 【HCV 2】Chair . The 25th Asian Pacific Association for the Study of the Liver 2016.02.22 International Convention Center Pamir, Tokyo（JAPAN）

  13. Nitta S, Asahina Y, Wakita T, Kato T. In vitro characterization and drug sensitivity analysis for HCV NS5A resistance-associated variants. The 25th Asian Pacific Association for the Study of the Liver 2016.02.22 International Convention Center Pamir, Tokyo（JAPAN）

  1. Shun Kaneko, Sei Kakinuma, Yasuhiro Asahina, Akihide Kamiya, Sayuri Nitta, Tomoyuki Tsunoda, Masato Miyoshi, Hiroko Nagata, Fumio Goto, Satoshi Otani, Miyako Murakawa, Fukiko Kawai-Kitahata, Yasuhiro Itsui, Mina Nakagawa, Seishin Azuma, Mamoru Watanabe. Human induced pluripotent stem cell-derived hepatic progenitor-like cells and hepatocyte-like cells as a model for interaction between hepatitis B virus and host cells. AASLD The Liver Meeting 2015 2015.11.16 San Francisco, CA

  2. Kawai-Kitahata F, Asahina Y, Tanaka S, Kakinuma S, Murakawa M, Nitta S, Watanabe T, Otani S, Goto F, Nagata H, Kaneko S, Azuma S, Itsui Y, Nakagawa M, Tanabe M, Maekawa S, Enomoto N, Watanabe M. Comprehensive analyses of mutations and hepatitis B virus integration in hepatocellular carcinoma with clinicopathological features. AASLD The Liver Meeting 2015 2015.11.14 San Francisco, CA

  3. Sayuri Nitta, Yasuhiro Asahina, Takaji Wakita, Takanobu Kato. Effects of Resistance Mutations of NS5A Inhibitor on Viral Production and Susceptibility to Anti-HCV Reagents in Recombinant Hepatitis C Viruses with NS5A of Genotype 1b. AASLD The Liver Meeting 2015 2015.11.13 San Francisco, CA

  4. Miyako Murakawa, Yasuhiro Asahina, Fukiko Kawai-Kitahata, Hiroko Nagata, Syun Kaneko, Sayuri Nitta, Takako Watanabe, Yasuhiro Itsui, Mina Nakagawa, Sei Kakinuma, Sayuki Iijima, Yasuhito Tanaka, Mamoru Watanabe, Yujiro Tanaka. Expression of IFNλ4 in liver is closely associated with non-response to antiviral therapy through the regulation of basal expression of ISGs in chronic hepatitis C patients but not in hepatitis B patients. AASLD The Liver Meeting 2015 2015.11.13 San Francisco, CA

  5. Takako Watanabe, Yasuhiro Asahina, Mina Nakagawa, Sei Kakinuma, Yasuhiro Itsui, Hiroko Nagata, Miyako Murakawa, Fukiko Kawai-Kitahata, Mika Miura, Shinya Maekawa, Nobuyuki Enomoto, Mamoru Watanabe. Serial change of resistant associated variants during early phase of NS3/4A triple therapy and the final virological outcome: analyses by ultra-deep sequencing technology. AASLD The Liver Meeting 2015 2015.11.13 San Francisco, CA

  6. Hiroko Nagata, Yasuhiro Itsui, Fukiko Kawai-Kitahata, Shun Kaneko, Miyako Murakawa, Sayuri Nitta, Mina Nakagawa, Seishin Azuma, Sei Kakinuma, Yasuhiro Asahina. Variations of the host genome and interaction of hepatitis B viral X protein associated with hepatocarcinogenesis. AASLD The Liver Meeting 2015 2015.11.13 San Francisco, CA

  7. Fukiko Kawai-Kitahata, Yasuhiro Asahina, Shun Kaneko, Hiroko Nagata, Fumio Goto, Satoshi Otani, Miki Taniguchi, Miyako Murakawa, Sayuri Nitta, Takako Watanabe, Megumi Tasaka-Fujita, Yuki Nishimura-Sakurai, Yasuhiro Itsui, Mina Nakagawa, Seishin Azuma, Sei Kakinuma, Shinji Tanaka , Minoru Tanabe, Nobuyuki Enomoto and Mamoru Watanabe. Gene alterations in TERT promoter, CTNNB1, and TP53 are closely associated with development and prognosis of hepatocellular carcinoma : Comprehensive analyses by next generation sequencing technology. The 3rd JSGE International Topic Conference 2015.04.24 Sendai

  8. Asahina Y, Kawai-Kitahata F, Kaneko S, Nagata H, Goto F, Otani S, Taniguchi M, Murakawa M, Nitta S, Watanabe T, Tasaka-Fujita M, Nishimura-Sakurai Y, Itsui Y, Nakagawa M, Azuma S, Kakinuma S, Tanaka S, Tanabe M, Enomoto N, Watanabe M. Gene alterations in tert promoter, CTNNB1, and TP53 are closely associated with development and prognosis of hepatocellular carcinoma: comprehensive analyses by next generation sequencing technology. 50th The International liver congress 2015, EASL 2015.04.22 Vienna

  1. Watanabe T, Asahina Y, Nakagawa M, Kakinuma S, Itsui Y, Taniguchi M, Murakawa M, Nagata H, Miura M, Maekawa S, Enomoto N, Watanabe M. Emergence or selection of resistant associated variant immediately after initiation of the therapy is predictive for failure of direct acting antiviral therapy:ultra-deep sequencing analyses for serial time points. The 65th. Annual Meeting of American Association for the Study of Liver Diseases（AASLD The Liver Meeting 2014) 2014.11.11 Boston

  2. Otani S, Kakinuma S, Watanabe M. Matrix Metalloproteinase-14 regulates the maturation of fetal hepatic stem/progenitor cells in mice. The 65th. Annual Meeting of American Association for the Study of Liver Diseases（AASLD The Liver Meeting 2014) 2014.11.11 Boston

  3. Murakawa M, Asahina Y, Nakagawa M, Kawai-Kitahata F, Taniguchi M, Nitta S, Watanabe T, Itsui Y, Kakinuma S, Sakamoto N, Watanabe M. Expression of IFNλ4 in liver and PBMC is closely associated with higher basal expression of ISGs and impaired induction of IL28B by interferon treatment in chronic hepatitis C non-responder patients. The 65th. Annual Meeting of American Association for the Study of Liver Diseases（AASLD The Liver Meeting 2014) 2014.11.11 Boston

  4. Kawai-Kitahata F, Asahina Y, Kaneko S, Nagata H, Goto F, Otani S, Taniguchi M , Murakawa M , Nitta S, Watanabe T, Itsui Y, Nakagawa M, Kakinuma S, Enomoto N, Watanabe M. Gene alterations in β-catenin and p53/cell cycle control pathway are closely associated with development and prognosis of hepatocellular carcinoma: Comprehensive analyses by next generation sequencing technology. The 65th. Annual Meeting of American Association for the Study of Liver Diseases（AASLD The Liver Meeting 2014) 2014.11.10 Boston

  5. Nakagawa M, Asahina Y, Taniguchi M, Watanabe T, Nishimura-Sakurai Y, Itsui Y, Azuma S, Kakinuma S, Tanaka Y, Watanabe M. Impact of host and therapeutic factors and resistant associated variants on response to interferon based-direct acting antiviral treatment in difficult-to-treat chronic hepatitis C patients. The 65th. Annual Meeting of American Association for the Study of Liver Diseases（AASLD The Liver Meeting 2014) 2014.11.09 Boston

  6. Otani S, Kakinuma S, Kamiya A, Goto F, Kaneko S, Azuma S, Asahina Y, Watanabe M. Matrix Metalloproteinase-14 controls differentiation of fetal hepatic stem/progenitor cells. Japan Digesive Disease Weeks 2014 2014.10.23 Kobe

  1. 谷口未樹、中川美奈、 朝比奈靖浩　柿沼　晴、東　正新、渡辺貴子、櫻井　幸、村川美也子、大谷賢志、河合富貴子、後藤文男、坂本直哉、渡辺　守. 慢性肝疾患における肝細胞癌とIL-6 の関連. 第49回日本肝臓学会総会 2013.06.06 京王プラザホテル（東京都新宿区）

  2. 新田沙由梨、朝比奈靖浩、柿沼　晴、坂本直哉、渡辺　守. ウイルス肝炎における自然免疫応答抑制メカニズムの解析. Liver Forum in Kyoto　第16回学術集会 2013.03.29 京都

To the head of this page.▲